SCHEMBL7533635

SCHEMBL7533635

[CH2]CN(C)C(=O)c1ccc(N(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
MAPT P10636 4/20 0.55
HPGD P15428 3/20 0.55
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
HDAC6 Q9UBN7 5/20 0.51
HDAC1 Q13547 4/20 0.51
HDAC8 Q9BY41 3/20 0.51
HDAC3 O15379 2/20 0.51
HDAC4 P56524 2/20 0.51
HDAC7 Q8WUI4 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC10 Q969S8 2/20 0.51
HDAC11 Q96DB2 2/20 0.51
HDAC9 Q9UKV0 2/20 0.51
HDAC5 Q9UQL6 2/20 0.51
RAB9A P51151 3/20 0.48
NPC1 O15118 3/20 0.48
MAPK1 P28482 2/20 0.44
POLB P06746 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7529748 0.80 MEN1 (0.57) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL294286 0.80 KMT2A (0.53) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL6836572 0.79 HDAC6 (0.57) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL7528191 0.79 HPGD (0.48) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL7531226 0.78 DRD2 (0.57) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL24783913 0.77 ALDH1A1 (0.67) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL123989 0.77 NSD2 (0.42) ALDH1A1HPGDHDAC6HDAC1
SCHEMBL5318145 0.77 NSD2 (0.60) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL3300602 0.75 ALDH1A1 (0.64) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL12380032 0.75 HDAC6 (0.54) ALDH1A1MAPTHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US claimed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO claimed
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US disclosed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO disclosed
WO-2000055179-A1 NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS ISIS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147331-A1 Methods for synthesis of oligonucleotides RNGTT, TYMP, PNP ALDH1A1 4843/4885MAPT 3054/4885HPGD 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.